key: cord-0820412-tmyvj3ok authors: Collins, Emilie C.; Carr, Michael J.; Kim, James Soo; Lewis, John; Maleque, Noble; Desai, Krisha; Chen, Lauren; Sevransky, Jon; Gaddh, Manila; Rouphael, Nadine; Hubbard, Jacqueline; Pendley, Andrew M. title: Immune thrombocytopenia in 2 healthy young women after the Pfizer‐BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination date: 2021-09-17 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12531 sha: 5822b4cd65b629f16d7bf9092c7d4324b7594ac4 doc_id: 820412 cord_uid: tmyvj3ok Immune thrombocytopenic purpura (ITP) is a rare complication associated with vaccines targeting various diseases, including influenza, measles‐mumps‐rubella, hepatitis B, and diphtheria‐tetanus‐pertussis. We report 2 cases of ITP in healthy 20‐year‐old and 21‐year‐old women presenting to Emory University in Atlanta, GA, 2 days after the second dose and 11 days after the first dose (respectively) of the Pfizer‐BioNTech messenger RNA severe acute respiratory syndrome coronavirus 2 vaccine. Both patients recovered quickly. With more than a billion doses of coronavirus disease 2019 vaccines safely administered worldwide as of May 2021, discussions with patients should put into perspective the low risks of vaccination against the enormous societal benefit of the coronavirus disease 2019 vaccine. Serious adverse events such as vaccine-induced immune thrombocytopenic purpura (ITP; previously observed in other vaccines) are a concern with worldwide coronavirus disease 2019 vaccinations. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Although its pathogenesis is unclear, ITP is characterized by a decrease in platelet count secondary to impaired production of and destruction of platelets. 5 Typical clinical presentations include petechiae, bruising, and mucosal bleeding and occasionally severe thrombotic complications. 1, 6 Although this syndrome is rare given the millions of safely administered doses, vigilance and awareness by frontline providers in considering this diagnosis is important during postvaccination clinical evaluation. We present 2 cases of acute ITP after the ITP is an autoimmune disorder characterized by mucocutaneous bleeding and thrombocytopenia with platelet levels <150,000/µL. The estimated incidence of ITP is 2 to 5 in 100,000 persons per year, with 50% of cases occurring in pediatric patients. 11, 12 There is a 2:1 female to male predominance. Pathogenesis is secondary to autoantibodies targeting multiple platelet glycoproteins, leading to macrophagemediated destruction and the inhibition of platelet production. 11 In adults, onset is typically chronic and insidious rather than acute. Petechiae and ecchymosis develop at platelet levels between 10,000 and 30,000/µL, and mucosal bleeding and hemorrhage are associated with levels <10,000/µL. 11 In this article, we described 2 cases of ITP in healthy young women presenting 2 to 11 days post-dose of the Pfizer-BioNTech messenger RNA severe acute respiratory syndrome coronavirus 2 vaccine with platelet counts of <20,000/µL treated successfully with IVIG and steroids, respectively. The 2 patients did not present any evidence of thrombocytopenia and thrombosis simultaneously, as has been reported with the Janssen, Johnson & Johnson, and AstraZeneca vaccines. This report also adds to the few reported cases of thrombocytopenia related to the Pfizer vaccine. Vaccines are safe with very low adverse event rates of 1 to 7 in 1 million. Vaccinations are a rare but known cause of ITP after vaccination against influenza, measles-mumps-rubella, hepatitis B, and diphtheriatetanus-pertussis. 2 It is incumbent on healthcare professionals in emergency, ambulatory, and inpatient settings to consider vaccine-related adverse effects on patients who are seen for these complications as well as reporting them to the US Department of Health and Human Services managed VAERS registry (https://vaers.hhs.gov/esub/index.jsp). It is also important for physicians to appropriately put into perspective for healthcare professionals, patients, and the public the very low rate of rare, treatable vaccine complications against the enormous societal benefit in the reduction of incidence and severity of coronavirus disease 2019 during this devastating pandemic. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine Familial thrombocytopenia flare-up following the first dose of mRNA-1273 covid-19 vaccine Immune thrombocytopenia in a 22-year-old post covid-19 vaccine Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine Thrombocytopenia following Pfizer and moderna SARS-CoV-2 vaccination Covid-19 and children with immune thrombocytopenia: emerging issues Idiopathic thrombocytopenic purpura and MMR vaccine Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS) A case-control study to assess the risk of immune thrombocytopenia associated with vaccines Immune thrombocytopenic purpura The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review Vaccine adverse events: separating myth from reality American society of hematology 2019 guidelines for immune thrombocytopenia Updated international consensus report on the investigation and management of primary immune thrombocytopenia Immune thrombocytopenia in 2 healthy young women after the Pfizer-BioNTech BNT16B2b2 messenger RNA coronavirus disease 2019 vaccination The authors declare no conflicts of interest.